2023
Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric‐Onset IBD Cohort
Kaplan J, Liu C, King E, Bass J, Patel A, Tung J, Chen S, Lissoos T, Candela N, Saeed S, Colletti R, Network I, Adler J, Baron H, Cabrera J, Dorsey J, Dykes D, Ebach D, Garin‐Laflam M, Gold B, Grunow J, Higuchi L, Jester T, Lapsia S, Leibowitz I, Linvlle T, Morhardt T, Moses J, Moulton D, Nasiri‐Blomgren S, Niklinska‐Schirtz B, Ogunmola N, Palomo P, Park K, Pashankar D, Pasternak B, Radano M, Samson C, Sandberg K, Schaefer M, Shashidhar H, Steiner S, Sullivan J, Tomer G, Verstraete S. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric‐Onset IBD Cohort. Journal Of Pediatric Gastroenterology And Nutrition 2023, 76: 566-575. PMID: 36804501, PMCID: PMC10097486, DOI: 10.1097/mpg.0000000000003734.Peer-Reviewed Original ResearchConceptsCrohn's diseaseUlcerative colitisLoss of responseFirst biologicSubsequent biologicsBiologic agentsBiologic medicationsBiologic treatmentAnti-tumor necrosis factor agentsUpper gastrointestinal tract involvementGastrointestinal tract involvementNecrosis factor agentsActive Crohn's diseaseFirst biologic agentIBD cohortInitial biologicSecond biologicTract involvementCorticosteroid useFactor agentsPediatric IBDBiologic initiationDisease courseUnivariate analysisSevere disease
2017
Biologics in Pregnancy and Breastfeeding
Gaidos J, Kane S. Biologics in Pregnancy and Breastfeeding. 2017, 81-99. DOI: 10.1007/978-3-319-60276-9_6.Peer-Reviewed Original ResearchInflammatory bowel diseaseBowel diseaseAnti-IL-12/ILAnti-TNFα inhibitorsAdverse pregnancy outcomesImportance of adherenceAppropriate medical treatmentTime of conceptionActive diseaseDisease remissionNeonatal outcomesPregnancy complicationsPreconception counselingPregnancy outcomesBiologic medicationsLifelong treatmentMedical treatmentPregnancyThird decadeDiseaseRecent evidenceRemissionBreastfeedingMedicationsOutcomes
2014
Understanding therapeutic pathways and comorbidities in psoriasis.
Gordon K, Strober B. Understanding therapeutic pathways and comorbidities in psoriasis. Seminars In Cutaneous Medicine And Surgery 2014, 33: s20-3. PMID: 24979540, DOI: 10.12788/j.sder.0067.Peer-Reviewed Original ResearchConceptsImmunologic pathwaysQuality of lifeJoint symptomsBiologic medicationsPathophysiologic pathwaysSystemic diseaseTherapeutic armamentariumInflammatory diseasesTherapeutic pathwaysPsoriasisKeratinocyte proliferationMedicationsHealth risksDiseasePathwayComorbiditiesMorbiditySymptomsArmamentariumMortality
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply